Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | SCN4A | P35499 | 1/20 | 0.54 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.54 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713351 | 0.98 | MMP9 (0.61) | MMP9MMP2LMNACYP2C9KCNH2 | |
| SCHEMBL3195931 | 0.95 | MMP9 (0.59) | MMP9MMP2LMNACYP2C9KCNH2 | |
| SCHEMBL1861823 | 0.95 | MMP9 (0.59) | MMP9MMP2LMNACYP2C9KCNH2 | |
| SCHEMBL30457291 | 0.79 | LMNA (0.53) | MMP9MMP2LMNACYP2C9KCNH2 | |
| SCHEMBL77738 | 0.74 | MMP2 (1.00) | MMP9MMP2CYP2C9KCNH2BLM | |
| SCHEMBL7340621 | 0.74 | MMP9 (0.57) | MMP9MMP2LMNACYP2C9KCNH2 | |
| SCHEMBL5447642 | 0.74 | MMP2 (0.44) | MMP9MMP2LMNAKCNH2ALDH1A1 | |
| SCHEMBL4038795 | 0.74 | MMP9 (0.57) | MMP9MMP2LMNACYP2C9KCNH2 | |
| SCHEMBL9841218 | 0.74 | NPSR1 (0.43) | MMP9MMP2LMNAKCNH2AKR1B1 | |
| SCHEMBL11042592 | 0.74 | MMP9 (0.57) | MMP9MMP2LMNACYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076346-B2 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | Taro Pharamaceutical Industries Ltd. (IL) | 2011-12-13 | — | — | US | claimed |
| US-20100144769-A1 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5 5-DIPHENYL BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-06-10 | — | — | US | claimed |
| EP-1781294-A4 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID | TARO PHARMA IND (IL) | 2007-12-26 | — | — | EP | claimed |
| EP-1781294-A2 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2007-05-09 | — | — | EP | claimed |
| US-20060122208-A1 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-08 | — | — | US | claimed |
| WO-2006026095-A2 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-09 | — | — | WO | claimed |
| EP-1625848-A1 | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid | Taro Pharmaceuticals North America, Inc. (KY) | 2006-02-15 | — | — | EP | claimed |
| US-8076346-B2 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | Taro Pharamaceutical Industries Ltd. (IL) | 2011-12-13 | — | — | US | disclosed |
| US-20100144769-A1 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5 5-DIPHENYL BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-06-10 | — | — | US | disclosed |
| US-7683071-B2 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | TARO PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2010-03-23 | — | — | US | disclosed |
| EP-2081576-A2 | METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES | Taro Pharmaceuticals North America, Inc. (KY) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008066704-A2 | METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132529-A1 | Method of improving bioavailability for non-sedating barbiturates | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-06-05 | — | — | US | disclosed |
| EP-1781294-A4 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID | TARO PHARMA IND (IL) | 2007-12-26 | — | — | EP | disclosed |
| EP-1781294-A2 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2007-05-09 | — | — | EP | disclosed |
| US-20060122208-A1 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-08 | — | — | US | disclosed |
| WO-2006026095-A2 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5,5-DIPHENYL BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-09 | — | — | WO | disclosed |
| EP-1625848-A1 | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid | Taro Pharmaceuticals North America, Inc. (KY) | 2006-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144769-A1 | COMPOSITION AND METHOD FOR IMPROVED BIOAVAILABILITY AND ENHANCED BRAIN DELIVERY OF 5 5-DIPHENYL BARBITURIC ACID | CYP3A5, CA5A, FABP7 | MMP9 2102/4885MMP2 2720/4885LMNA 2966/4885 |
| US-20080132529-A1 | Method of improving bioavailability for non-sedating barbiturates | MTNR1B, GABRB3, GABBR1 | MMP9 1648/4885MMP2 3057/4885LMNA 1968/4885 |
| US-20060122208-A1 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | CYP3A5, SLC1A5, HTR5A | MMP9 2205/4885MMP2 2893/4885LMNA 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.